

Oxidative and nitrative modifications of enkephalins by human neutrophils: effect of nitroenkephalin on leukocyte functional responses

Elisabetta Capuozzo · Laura Pecci ·
Federica Giovannitti · Alessia Baseggio Conrado ·
Mario Fontana

Received: 2 July 2011 / Accepted: 3 November 2011 / Published online: 24 November 2011
© Springer-Verlag 2011

Abstract Neutrophils play a major role in acute inflammation by generating reactive oxygen/nitrogen species. Opioid peptides, including enkephalins, are present at inflammation sites. Neutrophils contribute to protect against inflammatory pain by releasing opioid peptides. In this investigation, the ability of human polymorphonuclear cells to induce oxidative and nitrative modifications of Leu-enkephalin has been investigated *in vitro*. Activated human neutrophils mediate the oxidation of Leu-enkephalin resulting in the production of dienkephalin. In the presence of nitrite at concentrations observed during inflammatory and infectious process (10–50 μM), nitroenkephalin, a nitrated derivative of Leu-enkephalin, is additionally formed. The yield of nitroenkephalin increases with nitrite concentration and is significantly inhibited by the addition of catalase or 4-aminobenzoic acid hydrazide (ABAH), a specific inhibitor of peroxidases. These results suggest that neutrophils induce nitration of Leu-enkephalin by a mechanism that is dependent on myeloperoxidase activity and hydrogen peroxide. Oxidative/nitrative modifications of Leu-enkephalin have been also evidenced when cells were treated with the NO-donor molecule, DEANO. The nitrated enkephalin has been examined for its effect on leukocyte functional responses. The data reveal that nitroenkephalin at micromolar concentrations inhibits superoxide anion generation and degranulation of azurophilic granules of human polymorphonuclear cells. Moreover, nitroenkephalin inhibits spontaneous apoptosis of neutrophils, as evaluated by

measuring caspase-3 activity. Collectively, our data indicate that the nitrated enkephalin attenuates neutrophil activation and promotes the short-term survival of these cells, suggesting a possible role of the nitrocompound in the efficiency and resolution of inflammatory processes.

Keywords Enkephalin · Nitroenkephalin · Neutrophils · Protein nitration · Inflammation · Apoptosis

Abbreviations

ABAH	4-Aminobenzoic acid hydrazide
Ac-DEVD-AMC	Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (caspase-3 substrate)
DEANO	Diethylamine NONOate
fMLP	<i>N</i> -Formyl-methionyl-leucyl-phenylalanine
HRP	Horseradish peroxidase
Leu-enkephalin	Leucine enkephalin
MeO-Suc-Ala-Ala-Pro-Val-AMC	<i>N</i> -Methoxysuccinyl-Ala-Ala-Pro-Val-7-amido-4-methylcoumarin (elastase substrate)
MPO	Myeloperoxidase
ODQ	1 <i>H</i> -[1,2,4]Oxadiazole[4,3- <i>a</i>]quinoxalin-1-one
PMA	Phorbol 12-myristate 13-acetate
PMNs	Polymorphonuclear cells
SOD	Superoxide dismutase

E. Capuozzo · L. Pecci · F. Giovannitti ·
A. Baseggio Conrado · M. Fontana (✉)
Dipartimento di Scienze Biochimiche “A. Rossi Fanelli”,
Istituto di Biologia e Patologia Molecolari del CNR, Sapienza
Università di Roma, P.le Aldo Moro 5, 00185 Rome, Italy
e-mail: mario.fontana@uniroma1.it

Introduction

Enkephalins belong to a class of bioactive peptides known for their endogenous opiate agonist activity (Frederickson

1977; Hughes et al. 1975). Mainly enkephalins, endorphins and dynorphins represent the endogenous opioid peptides. Endorphins and enkephalins share a common amino-terminal sequence and exhibit a tyrosine residue at the amino terminus, which is essential for their biological activity (Terenius et al. 1976). The aromatic amino acid residues are especially susceptible to oxidation by various forms of reactive oxygen species (ROS). In particular, enkephalins and opioid peptides react easily with ROS giving rise to oxidized products (Fontana et al. 2001; Nagy et al. 2009; Rosei 2001).

Opioid peptides, including enkephalins, are present at inflammation sites (Padrós et al. 1989; Sibinga and Goldstein 1988; Vindrola et al. 1990). During inflammatory process, the migration of opioid-containing leukocytes to inflamed tissues is induced. The secretion of opioid peptides by polymorphonuclear cells (PMNs), monocytes and lymphocytes can relieve inflammatory pain by interacting with peripheral opioid receptors (Cabot 2001; Przewlocki et al. 1992; Rittner et al. 2001; Stein et al. 1990). Therefore, inflammatory response can be associated with the release of high levels of opioid peptides. It has been reported that opioid peptides, such as methionine-enkephalin and beta-endorphin, are involved in neutrophil priming and that beta-endorphin also exerts immunosuppressive potency (McCain et al. 1982; Pasnik et al. 1999). Opioid peptides have been reported to bind to specific receptors on human phagocytic leukocytes and to modulate the activation of neutrophils (Diamant et al. 1989; Lopker et al. 1980; Menzebach et al. 2003).

Activated neutrophils produce a variety of powerful inflammatory mediators such as reactive oxygen species, enzymes and cytokines that play a key role in the host defenses against invading microorganisms, but can also be responsible for tissue damage. The reactive oxygen species are produced by neutrophils as a result of NADPH oxidase activation (reactions named “respiratory burst”) (Hampton et al. 1998; Witko-Sarsat et al. 2000). NADPH oxidase can be activated by various stimuli such as chemotactic peptide, *N*-formyl-methionyl-leucyl-phenylalanine (fMLP) or phorbol 12-myristate 13-acetate (PMA). Neutrophil function in vivo can be also regulated through NO-dependent mechanisms (Belenky et al. 1993; Fialkow et al. 2007; Moilanen et al. 1993). Nitric oxide (NO) modulates neutrophil pro-inflammatory responses and plays a protective role against priming and activation of these cells (Armstrong 2001; Clancy et al. 1992; Dal Secco et al. 2003; Grisham et al. 1999). However, when generated at elevated levels during inflammation by inducible NO synthase, NO is readily transformed into potent nitrating and oxidizing species, including peroxynitrite (ONOO⁻), nitrogen dioxide radical (NO₂), and nitrous acid (HONO) (Pryor and Squadrito 1995; Radi et al. 2001), which can modify both

the structure and the function of numerous biomolecules (Eiserich et al. 1998a; Lim et al. 2002; Vadseth et al. 2004; Quijano et al. 2005; Souza et al. 2008). It has been observed that various reactive nitrogen species react in vitro with Leu-enkephalin. As a consequence of these reactions, the tyrosine amino-terminal residue of enkephalin is converted either to 3-nitrotyrosine producing nitro-enkephalin or dityrosine with the production of an enkephalin dimer, the dienkephalin (Fontana et al. 2006). Up to now, no study has been published on nitrative biochemistry of enkephalins with neutrophil-generated reactive oxidants.

In the present investigation, we explored the ability of human PMNs to induce oxidative/nitrative modifications of Leu-enkephalin. Moreover, the nitrated enkephalin has been examined for its effect on leukocyte functional response. The data reveal that nitroenkephalin inhibits the respiratory burst and degranulation of azurophilic granules of human PMNs and their spontaneous apoptosis in vitro. These findings are of potential interest, inasmuch nitroenkephalin may act as modulator of tissue inflammatory response.

Materials and methods

Chemicals

Leucine-enkephalin (Leu-enkephalin), horseradish peroxidase (HRP), diethylamine NONOate sodium salt (DEANO), phorbol 12-myristate 13-acetate (PMA), *N*-formyl-Met-Leu-Phe (fMLP), *N*-methoxysuccinyl-Ala-Ala-Pro-Val-7-amido-4-methylcoumarin (MeO-Suc-Ala-Ala-Pro-Val-AMC, elastase substrate), acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC, caspase-3 substrate), porcine pancreas elastase, human recombinant caspase-3, naloxone and 4-aminobenzoic acid hydrazide (ABAH) were obtained from Sigma-Aldrich, Inc (St. Louis, MO, USA). 3-Nitrotyrosine, potassium nitrite, hydrogen peroxide, cytochrome *c* from horse heart and cytochalasin B were from Fluka Chemie GmbH (Buchs, CH). 1*H*-[1,2,4]oxadiazole [4,3-*a*]quinoxalin-1-one (ODQ, guanylate cyclase inhibitor) was from Alexis Co (Lausen, CH). All other chemicals were of analytical grade.

Synthesis and purification of nitroenkephalin

Nitroenkephalin was enzymatically synthesized via nitration of Leu-enkephalin by peroxidase-catalyzed oxidation of nitrite. Briefly, Leu-enkephalin (2 mM) was incubated with 1 μM horseradish peroxidase (HRP) and 10 mM potassium nitrite in 20 mM K-phosphate buffer at pH 7.4.

The reaction was started by the addition of 1 mM H₂O₂ and allowed to proceed at 37°C. The reaction was stopped after 1 h by the addition of 10 nM catalase. Aliquots of the reaction mixture were chromatographed on HPLC to accomplish the purification of nitroenkephalin. Elution was performed on a Prep Nova-Pak HR C₁₈ column (7.8 × 300 mm; 6 µm particle size). The mobile phases were—A: 0.2% aqueous trifluoroacetic acid containing 10% acetonitrile; B: acetonitrile:water (50:50, v/v); linear gradient: from A to 100% B over 30 min; and flow rate: 1.5 mL/min. The eluent was monitored at 274 and 360 nm and the fractions eluting between 28 and 30 min, corresponding to nitroenkephalin, were pooled and lyophilized (freeze/dried). The product was analyzed by HPLC as already described (Fontana et al. 2006) and nitroenkephalin was quantified from peak area using 3-nitrotyrosine as reference standard. Nitroenkephalin was stored in K-phosphate buffer, pH 7.4, at −20°C until use.

Isolation of neutrophils

Leukocytes were purified from heparinized human blood freshly drawn from healthy donors. Leukocyte preparations containing 90–98% neutrophils and apparently free of contaminating erythrocytes were obtained by a one-step procedure involving centrifugation of blood samples layered on Ficoll-Hypaque medium (Polymorphprep, Axis-Shield, Oslo, Norway) (Ferrante and Thong 1980). The cells were suspended in isotonic phosphate-buffered saline, pH 7.4, with 5 mM glucose and stored on ice. Each preparation produced cells with a viability higher than 90% up to 6 h after purification. The viability of the cells was measured by trypan blue exclusion test.

Oxidative/nitrative modifications of Leu-enkephalin by neutrophils

Human PMNs (2×10^6 cells) suspended in phosphate-buffered saline containing 0.5 mM MgCl₂, 0.5 mM CaCl₂ and 5 mM glucose were incubated with 1 mM Leu-enkephalin at 37°C in the absence or in the presence of different concentrations of potassium nitrite. After 5 min of incubation, PMNs were stimulated by the addition of 1 µg/mL PMA or 0.1 µM fMLP. Cytochalasin B (1 µg/mL) was added to f-MLP-stimulated PMNs. Reactions were terminated by placing tubes on ice and immediately adding SOD (90 U/mL) and catalase (500 U/mL) to scavenge residual oxidants. PMNs were pelleted by centrifugation (1,200g, 5 min, 4°C) and the products in the supernatant determined by HPLC as already described (Fontana et al. 2006). When used, ABAH (100 µM final concentration) was added to the incubation mixture 5 min before neutrophil activation.

Respiratory burst of neutrophils

Superoxide production by NADPH oxidase was estimated by measuring the rate of superoxide dismutase-inhibitable reduction of cytochrome *c* at 550 nm ($\epsilon = 21,100 \text{ M}^{-1} \text{ cm}^{-1}$ for ferrocytochrome *c*) by a modification of the method described by Lemheyer et al. (1979). The incubation mixture contained 2×10^6 cells/mL, 80 µM cytochrome *c* in phosphate-buffered saline containing 0.5 mM MgCl₂, 0.5 mM CaCl₂ and 5 mM glucose. After 3 min of preincubation at 37°C, the reaction was started by adding 1 µg/mL PMA or 0.1 µM fMLP. Cytochalasin B (1 µg/mL) was added to fMLP-stimulated PMNs. The controls contained, in addition, 20 µg/mL superoxide dismutase. Steady-state velocity of superoxide production was estimated from the linear part of the reaction curve. Where used, the soluble guanylate cyclase inhibitor 1*H*-[1,2,4]oxadiazole[4,3-*a*]quinoxalin-1-one (ODQ, 4 µM) was preincubated 20 min with cells before the assay.

Determination of neutrophils degranulation by elastase release

Degranulation of azurophilic granules was determined by elastase release (Sklar et al. 1982). Elastase release was measured by hydrolysis of the elastase substrate (MeO-Suc-Ala-Ala-Pro-Val-AMC). Briefly, isolated neutrophils (2×10^6 cells/mL) were resuspended in phosphate-buffered saline containing 0.5 mM MgCl₂, 1 mM CaCl₂, 5 mM glucose and 1 µg/mL cytochalasin B at 37°C. The elastase substrate (MeO-Suc-Ala-Ala-Pro-Val-AMC) was added at a final concentration of 40 µM. After 3 min of preincubation at 37°C, the reaction was started by adding 1 µM fMLP, and elastase activity was monitored fluorometrically (excitation wavelength 380 nm, emission wavelength 460 nm).

Detection of neutrophil apoptosis by caspase-3 activity assay

Caspase-3 activity was tested in neutrophil lysates by measuring the release of the fluorescent 7-amino-4-methylcoumarin (AMC) moiety from the synthetic substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC). Neutrophils (5×10^6 cells), preincubated at 37°C for 3.5 h in phosphate-buffered saline containing 0.5 mM MgCl₂, 1 mM CaCl₂ and 5 mM glucose were collected by centrifugation and lysed in 0.5 mL volumes of 50 mM HEPES, 5 mM 3-[3-(cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 5 mM dithiothreitol (DTT), pH 7.4, 10 µM 4-amidinophenylmethanesulfonyl fluoride (APMSF), 10 µg/mL pepstatin and 10 µg/mL aprotinin. The reaction was started by adding 100 µL aliquots

of the lysates in 2 mL solutions containing 16 μM Ac-DEVD-AMC, 20 mM HEPES, 0.1% CHAPS, 5 mM DTT and 2 mM EDTA, pH 7.4. The assay mixture was incubated at 20°C in the dark for 1 h. The fluorescence (excitation wavelength 360 nm, emission wavelength 460 nm) increase was compared with an appropriate blank control containing 10 μM acetyl-Asp-Glu-Val-Asp-al, a specific caspase-3 inhibitor (Nicholson et al. 1995) or a standard preparations of recombinant caspase-3 (Sigma). A calibration curve obtained with standard AMC solutions was employed for quantitative analysis.

Statistical analysis

Results are expressed as mean \pm SD for at least three separate experiments. Graphics and data analysis were performed using GraphPAD prism 4 software. Statistical analyses were performed using the ANOVA and Bonferroni post hoc test. $p \leq 0.05$ was deemed significant.

Results

Oxidative/nitrative modifications of Leu-enkephalin by neutrophils

Human neutrophils utilize myeloperoxidase (MPO)/ H_2O_2 / NO_2^- system to generate reactive nitrogen species (Brennan et al. 2002; Eiserich et al. 1998b). Recently, we reported that oxidants formed by this enzymatic system are able to convert the tyrosine amino-terminal residue of Leu-enkephalin either to 3-nitrotyrosine producing nitroenkephalin or to dityrosine with the production of an enkephalin dimer, the dienkephalin (Fontana et al. 2006). Figure 1 shows that 30 min incubation of 1 mM Leu-enkephalin with human PMNs activated with PMA yielded a detectable level ($0.82 \pm 0.10 \mu\text{M}$) of dienkephalin. Addition of NO_2^- to this reaction system produced nitroenkephalin as an additional product. The extent of the conversion of Leu-enkephalin to the nitroderivative was found to increase with the concentration of nitrite added, while dienkephalin production leveled off at approximately $25 \mu\text{M}$ NO_2^- . At higher nitrite concentrations ($>200 \mu\text{M}$), the yield of nitroenkephalin exceeded that of dienkephalin (data not shown). Unstimulated PMNs did not induce any modification of Leu-enkephalin.

To elucidate the mechanism by which NO_2^- participates in PMN-mediated nitration reaction, the system was investigated in the presence of SOD and catalase. As seen in Fig. 1 (inset), SOD exhibited only a marginal effect on the production of nitroenkephalin, whereas catalase strongly reduced the yield of the nitropeptide. In addition, 4-aminobenzoic acid hydrazide (ABAH), an inhibitor of




Fig. 1 Oxidative/nitrative modification of Leu-enkephalin by PMA-stimulated neutrophils. Leu-enkephalin (1 mM) was incubated with 2×10^6 neutrophils at 37°C and potassium nitrite (0–200 μM). After 5 min, neutrophils were stimulated by the addition of 1 $\mu\text{g}/\text{mL}$ PMA. After 30 min, the reaction was stopped by the addition of SOD (90 U/mL) and catalase (500 U/mL). Neutrophils were pelleted by centrifugation and the reaction products in the supernatant were determined by HPLC. *Inset*, effect of SOD, catalase and ABAH on Leu-enkephalin nitration by PMA-stimulated neutrophils. Leu-enkephalin (1 mM) was incubated with 2×10^6 neutrophils at 37°C and 100 μM potassium nitrite in the presence of SOD (90 U/mL), catalase (500 U/mL) or ABAH (100 μM). The reaction was stopped after 30 min as above and the reaction products were determined by HPLC

MPO (Kettle et al. 1995), completely abolished nitroenkephalin formation. Collectively, these data support a mechanism for PMN-mediated nitration of enkephalin that is dependent on active MPO and hydrogen peroxide.

The oxidative/nitrative modifications of Leu-enkephalin by human neutrophils have been also investigated in the presence of an NO-producing system. PMNs activated with PMA or fMLP were exposed to a continuous flux of NO, using the NO-donor molecule DEANO. The yields of dienkephalin and nitroenkephalin produced after 30 min of incubation with 1 mM Leu-enkephalin are reported in Fig. 2. It can be seen that PMNs activated with PMA are capable of nitrating and oxidizing enkephalin with higher efficiency compared with fMLP-activated PMNs.

Effect of nitroenkephalin on superoxide generation by human PMNs

To investigate if enkephalin, undergoing oxidative/nitrative modification, could influence neutrophil functions, the nitrated peptide was explored for its effect on respiratory burst. Addition of 100 μM Leu-enkephalin or nitroenkephalin to human PMN in suspension did not stimulate superoxide generation. However, nitroenkephalin added to neutrophils 2 min before activation by 1 $\mu\text{g}/\text{mL}$ PMA or 0.1 μM fMLP led to a concentration-dependent inhibition of superoxide generation (Fig. 3b). Nitroenkephalin half maximal inhibition of superoxide anion generation was 48.4 ± 1.3 and $66.9 \pm 1.3 \mu\text{M}$ for PMA- and fMLP-




Fig. 2 Oxidative/nitrative modification of Leu-enkephalin by PMA- or fMLP-stimulated neutrophils in the presence of the nitric oxide donor, DEANO. Leu-enkephalin (1 mM) was incubated with 2×10^6 neutrophils at 37°C and 1 mM DEANO. After 5 min, neutrophils were stimulated by the addition of 1 μg/mL PMA or 0.1 μM fMLP. Cytochalasin B (1 μg/mL) was added to f-MLP-stimulated PMNs. After 30 min, the reaction was stopped by the addition of SOD (90 U/mL) and catalase (500 U/mL). Neutrophils were pelleted by centrifugation and the reaction products in the supernatant were determined by HPLC; *n.d.* not detected. Control values are without DEANO. **a** Nitroenkephalin; **b** Dienkephalin

stimulated human PMNs, respectively. Control experiments, using the enzymatic system xanthine/xanthine oxidase to generate superoxide anion, indicated that nitroenkephalin did not act as a scavenger of superoxide anion (not shown). In Fig. 4a, it is also shown that Leu-enkephalin and the free nitrated amino acid, 3-nitrotyrosine, did not affect the oxidative burst of PMA-stimulated neutrophils.

Previous investigations indicated that NO or NO-releasing compounds increased cyclic GMP (cGMP) in human neutrophils with concomitant inhibition of PMN functions including superoxide anion generation (Moilanen et al. 1993). To evaluate the possible involvement of the




Fig. 3 Inhibition of neutrophil superoxide anion generation in response to either PMA or fMLP by nitroenkephalin. Superoxide anion generation was estimated by measuring cytochrome *c* reduction as described in “Materials and methods”. Neutrophils (2×10^6 cells) in 1 mL phosphate-buffered saline containing 80 μM cytochrome *c* at 37°C were activated by 1 μg/mL PMA or 0.1 μM fMLP and the absorbance at 550 nm was monitored. Nitroenkephalin was added 2 min before activation. Steady-state velocity of superoxide production was estimated from the linear part of the reaction curve. **a** Time course of superoxide anion generation by PMA-activated neutrophils with/without 20 μM nitroenkephalin. **b** Dose-dependent inhibition of PMA- and fMLP-stimulated neutrophil superoxide anion generation by nitroenkephalin. **b** Inset, dose-dependent inhibition of PMA-stimulated neutrophil superoxide anion generation by ≤ 5 μM nitroenkephalin. $**p < 0.05$, compared with the control value (PMA-stimulated neutrophil superoxide anion generation in the absence of nitroenkephalin)

NO/cGMP system in the mechanism of inhibition exerted by nitroenkephalin, fMLP-stimulated human PMNs were incubated with nitroenkephalin in the presence of the soluble guanylate cyclase inhibitor, ODQ. It can be observed that the inhibitory effect of nitroenkephalin was not reversed by the presence of ODQ indicating that the inhibition of superoxide anion generation is not cGMP mediated (Fig. 4b).

Enkephalins are known to bind to specific opioid receptors on human neutrophils (Menzebach et al. 2003). To evaluate whether the inhibitory activity of




Fig. 4 Comparison of the effect of nitroenkephalin with various bioactive molecules on PMA- or fMLP-stimulated neutrophil superoxide anion generation. Superoxide anion generation was estimated by measuring cytochrome *c* reduction as described in “Materials and methods”. Neutrophils (2×10^6 cells) in 1 mL phosphate-buffered saline containing 80 μ M cytochrome *c* at 37°C were activated by 1 μ g/mL PMA or 0.1 μ M fMLP, and the absorbance at 550 nm was monitored. Nitroenkephalin and other test compounds were added 2 min before activation. ODQ was preincubated 20 min with cells before the assay. Steady-state velocity of superoxide production was estimated from the linear part of the reaction curve. **a** Comparison of the effect of 100 μ M nitroenkephalin, 100 μ M Leu-enkephalin and 100 μ M 3-nitrotyrosine on PMA-stimulated neutrophil superoxide anion generation. **b** Comparison of the effect with/without nitroenkephalin of 100 μ M naloxone and 4 μ M ODQ on fMLP-stimulated neutrophil superoxide anion generation. *** $p < 0.001$, compared with the corresponding control (the first column of each panel)

nitroenkephalin is mediated by its binding to opioid receptors, the effect of nitroenkephalin on respiratory burst was examined in the presence of naloxone, a competitive opioid receptor antagonist. Figure 4b shows that the

addition of 100 μ M naloxone did not modify the inhibitory effect of nitroenkephalin on superoxide anion release, suggesting that the mechanism of inhibition does not involve opioid receptors.

Nitroenkephalin attenuation of fMLP-induced degranulation of human PMNs

Pretreatment of neutrophils with 100 μ M nitroenkephalin strongly reduced fMLP-induced azurophilic degranulation as evaluated by measuring the activity of released elastase (Fig. 5a). Figure 5b shows that the inhibitory effect of nitroenkephalin was concentration-dependent with half




Fig. 5 Inhibition of fMLP-stimulated neutrophil degranulation by nitroenkephalin. Degranulation activity was determined by elastase release. Elastase activity was measured by hydrolysis of the elastase substrate (MeO-Suc-Ala-Ala-Pro-Val-AMC) as described in “Materials and methods”. Neutrophils (2×10^6 cells) were incubated with 1 μ g/mL cytochalasin B and 40 μ M MeO-Suc-Ala-Ala-Pro-Val-AMC at 37°C for 3 min before activation with 1 μ M fMLP, as indicated by arrows. Nitroenkephalin was added 2.5 min before activation. **a** Time course of elastase release by fMLP-activated neutrophils with/without 100 μ M nitroenkephalin. **b** Dose-dependent inhibition of fMLP-stimulated neutrophil elastase release by nitroenkephalin. **b Inset**, comparison of elastase release by fMLP-stimulated neutrophils in the absence (control) and presence of 100 μ M nitroenkephalin, 100 μ M Leu-enkephalin and 100 μ M 3-nitrotyrosine. * $p < 0.05$ and *** $p < 0.001$, compared with the control (the first column of the panel)

maximal inhibition of $13.8 \pm 1.5 \mu\text{M}$. Leu-enkephalin ($100 \mu\text{M}$) was ineffective and 3-nitrotyrosine ($100 \mu\text{M}$) showed a 37% inhibition of elastase release (Fig. 5b, inset). Addition of nitroenkephalin to unstimulated PMNs had no effect on their degranulation activity. Control experiments using commercial elastase from porcine pancreas indicate that nitroenkephalin ($100 \mu\text{M}$) did not affect the elastase activity (not shown).

Influence of nitroenkephalin and Leu-enkephalin on neutrophil spontaneous apoptosis

Neutrophil spontaneous apoptosis was evaluated by measuring caspase-3 activity in lysates of neutrophils (5×10^6 cells/mL) that were preincubated at 37°C for 3.5 h. When the preincubation step was performed in the presence of Leu-enkephalin (5 – $100 \mu\text{M}$), no considerable effect on the caspase-3 activity was observed (Fig. 6). Conversely, the addition of nitroenkephalin induced a decrease of caspase-3 activity that was concentration dependent. With $50 \mu\text{M}$ nitroenkephalin, the reduction of caspase-3 activity was close to 40% ($p < 0.05$). Control experiments indicated that neither nitroenkephalin nor the parent peptide Leu-enkephalin affected the activity of recombinant caspase-3 (not shown).

To rule out toxic effects exerted by nitroenkephalin, cell viability was measured by the trypan blue exclusion test. Neutrophil viability was evaluated after incubation of the cells at 37°C for 3.5 h. Nitroenkephalin showed no effect in the range 10 – $100 \mu\text{M}$ (Fig. 6).




Fig. 6 Effect of Leu-enkephalin and nitroenkephalin on neutrophil caspase-3 activity. Neutrophils (2×10^6 cells) were incubated in the absence (control) and in the presence of various concentrations of Leu-enkephalin or nitroenkephalin at 37°C for 3.5 h. Intracellular caspase-3 activity was determined as described in “Materials and methods”. Cell viability (filled diamonds) was estimated by the trypan blue exclusion test and is expressed as percentage of untreated cells. Values are given as mean \pm SD ($n = 4$). * $p < 0.05$, and *** $p < 0.001$, compared with the control value

Discussion

In a recent paper, we showed that reactive nitrogen species, such as peroxynitrite or nitrite/singlet oxygen or peroxidase-catalyzed oxidation of nitrite, are capable of nitrating and oxidizing the bioactive peptide Leu-enkephalin to give nitroenkephalin and dienkephalin (Fontana et al. 2006). The results presented in this paper demonstrate that activated human neutrophils, in the presence of nitrite, mediate nitration and dimerization of Leu-enkephalin leading to nitroenkephalin and dienkephalin formation. It should be noted that addition of nitrite at concentrations observed during inflammatory and infectious process (10 – $50 \mu\text{M}$) (Farrel et al. 1992; Torre et al. 1996) induced both nitration and dimerization of Leu-enkephalin. The relative yields of nitroenkephalin and dienkephalin produced by human PMNs depend on nitrite concentration. At low concentrations of nitrite, dimerization of enkephalin is the predominant pathway, whereas at higher concentration of nitrite ($>200 \mu\text{M}$), nitroenkephalin is the main product. These findings suggest that enkephalin dimerization competes with nitroenkephalin formation, which becomes more significant with increasing levels of nitrite. As already reported, PMN-mediated nitration reactions involve reactive oxygen/nitrogen species and myeloperoxidase activity (Brennan et al. 2002; Eiserich et al. 1998b). Accordingly, our data show a critical role of hydrogen peroxide as revealed by inhibition of the nitroenkephalin formation in the presence of catalase. Furthermore, inhibition of myeloperoxidase by ABAH completely abolishes the conversion of enkephalin to nitroenkephalin. Collectively, these results support a mechanism for PMN-mediated modification of Leu-enkephalin that is dependent on myeloperoxidase activity and hydrogen peroxide production. Nitrative/oxidative modifications of tyrosine by MPO in the presence of hydrogen peroxide and nitrite has been attributed to direct action of MPO Compound I and II on both nitrite and tyrosine producing nitrogen dioxide radical (NO_2^\cdot) and tyrosyl radical (Tyr^\cdot), respectively (Burner et al. 2000). Then, Tyr^\cdot can either react with NO_2 ($k = 1.3 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$) to form nitrotyrosine or dimerize ($k = 2.25 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$) to give dityrosine (Hunter et al. 1989; Prutz et al. 1985). With enkephalin as a target, the tyrosine amino-terminal residue of the peptide can be converted either to 3-nitrotyrosine producing nitroenkephalin or to dityrosine, with the production of an enkephalin dimer, the dienkephalin.

Recently, it has been reported that activated neutrophils use MPO to oxidize Leu-enkephalin to their corresponding tyrosyl free radical, which preferentially reacts with respiratory burst-derived superoxide anion ($k = 1.5 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$) (Jin et al. 1993) to form a hydroperoxide derivative (Nagy et al. 2010). Here, we demonstrate that stimulated neutrophils, in the presence of nitrite, promote as a further

modification of enkephalins nitration of amino-terminal tyrosine residue to give nitroenkephalin. As the rate constant for the reaction of tyrosyl radical with superoxide anion is similar to that with NO_2 ($k = 4.5 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$) (Goldstein et al. 1998), it is possible (but remain to be proved) that Leu-enkephalin may be partly oxidized via superoxide anion-mediated mechanism also under our experimental conditions.

Nitrite is the major end product of NO metabolism, and inducible NO synthase is contained in neutrophil primary granules (Evans et al. 1996). To simulate a physiological mechanism of nitrite formation, activated neutrophils were exposed to a continuous flux of NO, using the NO-donor molecule, DEANO. These conditions also promoted nitration and dimerization of Leu-enkephalin. Although NO readily reacts with superoxide anion to form the potent oxidative/nitrative agent, peroxynitrite, it has been previously reported that NO fluxes induce tyrosine nitration predominantly via MPO/ H_2O_2 -dependent oxidation of nitrite to NO_2 . In line with this, we found that with fMLP-activated PMNs, the yield of nitroenkephalin was 1.6-fold less, a consequence possibly related to decreased MPO release (Eiserich et al. 1998b).

In our studies on the PMNs-mediated nitrative reactions, we used enkephalin concentrations much higher than those present in plasma. Circulating enkephalins are normally in the nanomolar range; however, their amount can significantly increase under some pathological conditions (Clement-Jones et al. 1980; Pierzchala and Van Loon 1990; Semmoum et al. 2001). Moreover, locally synthesized enkephalins in inflamed tissues could produce interstitial enkephalin concentrations much higher than those observed in plasma. The concept of local enkephalin is supported by the finding that inflammatory cells contain enkephalins and the mRNA for their precursor, proenkephalin (Padrós et al. 1989; Przewlocki et al. 1992; Rittner et al. 2001). Furthermore, enkephalins undergo rapidly hydrolysis, underestimating the actual concentration.

It has been shown that opioid peptides may prime or modulate the activity of leukocytes (McCain et al. 1982; Menzebach et al. 2003; Pasnik et al. 1999; Rabgaoui et al. 1993; Sulowska et al. 2002). To characterize a possible bioactivity of the nitrated enkephalin, its influence on human neutrophil functional responses has been examined. Nitroenkephalin at micromolar concentrations inhibits neutrophil activation in response to PMA or fMLP, as indicated by the inhibition of superoxide anion generation and of degranulation of azurophilic granules. Under the same experimental conditions, the parent peptide, Leu-enkephalin, showed no inhibitory activity on these human neutrophil functions.

Neutrophil apoptosis is an important process because it provides a signal for PMN removal (Savill and Fadok 2000) and it results in the loss of functional neutrophil responsiveness (Lee et al. 1993; Savill et al. 2002; Simon 2003). Thus, modulation of apoptosis may have a major effect on the inflammatory process. As several studies suggested a critical role of caspase-3 in both spontaneous and Fas receptor-mediated apoptosis in neutrophils (Daigle and Simon 2001; Khwaja and Tatton 1999; Ottonello et al. 2002; Pongracz et al. 1999; Weinmann et al. 1999), we studied the effect of nitroenkephalin and the parent peptide on spontaneous apoptosis by measuring the caspase-3 activity in cell lysates (Fig. 6). Our results indicate that the nitroenkephalin influences the life span of human PMNs by inhibition of spontaneous apoptosis.

It is recognized that the production of reactive oxygen species by activated cells accelerate the apoptosis and that superoxide release is required for spontaneous apoptosis (Kettritz et al. 1997; Ottonello et al. 2002; Scheel-Toellner et al. 2004). In agreement, blood neutrophils from patients with a genetic defect of NADPH oxidase, thus not generating reactive oxygen species, demonstrate delayed spontaneous apoptosis (Kasahara et al. 1997; Hampton et al. 2002; Savill et al. 1989). Thus, it is possible that the nitrated enkephalin decreases spontaneous apoptosis of human neutrophils by inhibiting superoxide anion production. Accordingly, the parent Leu-enkephalin, which does not inhibit superoxide anion generation, does not decrease spontaneous apoptosis.

The cellular mechanism by which nitroenkephalin exerts an inhibitory effect on neutrophil functional responses requires further study. At the moment, the observation that naloxone, a competitive opioid receptor antagonist, failed to reverse the inhibition of superoxide anion generation by nitroenkephalin, indicates that the opioid receptor is not involved in the mechanism of inhibition. Furthermore, cGMP has been observed to have an inhibitory effect on fMLP-induced responses (Ervens et al. 1991). Under our experimental conditions, the soluble guanylate cyclase inhibitor, ODQ, did not interfere with the inhibitory effect of nitroenkephalin providing evidence that the inhibition on fMLP-induced respiratory burst occurs through a cGMP-independent pathway.

In conclusion, the results of our *in vitro* studies indicate that Leu-enkephalin, present at inflammation sites, might exert regulatory effects on the efficiency of inflammatory processes, after its conversion to nitroenkephalin, induced by activated human neutrophils. Although the bioactivity of nitroenkephalin has been observed at concentrations higher than those eventually formed *in vivo*, our findings may lead to further understanding of biochemical

inflammatory mechanisms and open the route to the development of new therapeutic strategies for inflammation.

Conflict of interest The authors declare that they have no conflict of interest.

References

- Armstrong R (2001) The physiological role and pharmacological potential of nitric oxide in neutrophils activation. *Int Immunopharmacol* 1:1501–1512
- Belenky SN, Robbins RA, Rennard SI, Gossman GL, Nelson KJ, Rubinstein I (1993) Inhibitors of nitric oxide synthase attenuate human neutrophil chemotaxis in vitro. *J Lab Clin Med* 122:388–394
- Brennan M-L, Wu W, Fu X, Shen Z, Song W, Frost H, Vadseth C, Narine L, Lenkiewicz E, Borchers MT, Lusi AJ, Lee JJ, Lee NA, Abu-Soud HM, Ischiropoulos H, Hazen SL (2002) A tale of two controversies. Defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. *J Biol Chem* 277:17415–17427
- Burner U, Furtmüller PG, Kettle AJ, Koppenol WH, Obinger C (2000) Mechanism of reaction of myeloperoxidase with nitrite. *J Biol Chem* 275:20597–20601
- Cabot PJ (2001) Immune-derived opioids and peripheral antinociception. *Clin Exp Pharmacol Physiol* 28:230–232
- Clancy RM, Leszczynska-Piziak J, Abramson SB (1992) Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. *J Clin Invest* 90:1116–1121
- Clement-Jones V, Lowry PJ, Rees LH, Besser GM (1980) Met-enkephalin circulates in human plasma. *Nature* 283:295–297
- Daigle I, Simon HU (2001) Critical role for caspase 3 and 8 in neutrophil but not eosinophil apoptosis. *Int Arch Allergy Immunol* 126:147–156
- Dal Secco D, Paron JA, de Oliveira SH, Ferreira SH, Silva JS, de Querioz Cunha F (2003) Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and induces apoptosis. *Nitric Oxide* 9:153–164
- Diamant M, Henricks PA, Nijkamp FP, de Wied D (1989) Beta-endorphin and related peptides suppress phorbol myristate acetate-induced respiratory burst in human polymorphonuclear leukocytes. *Life Sci* 45:1537–1545
- Eiserich JP, Patel RP, O'Donnel VB (1998a) Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. *Mol Aspects Med* 19:221–357
- Eiserich JP, Hristova M, Cross CE, Daniels Jones A, Freeman BA, Halliwell B, Van Der Vliet A (1998b) Formation of nitric oxide-derived oxidants by myeloperoxidase in neutrophils. *Nature* 391:393–397
- Ervens J, Schultz G, Seifert R (1991) Differential inhibition and potentiation of chemoattractant-induced superoxide formation in human neutrophils by the cell-permeant analogue of cyclic GMP, N₂, 2'-O-dibutyl guanosine 3':5'-cyclic monophosphate. *Naunyn Schmiedeberg Arch Pharmacol* 343:370–376
- Evans TJ, BATTERY LDK, Carpenter A, Springall DR, Polak JM, Cohen J (1996) Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. *Proc Natl Acad Sci USA* 93:9553–9558
- Farrel AJ, Blake DR, Palmer RMJ, Moncada S (1992) Increased concentration of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. *Ann Rheum Dis* 51:1219–1222
- Ferrante A, Thong YH (1980) Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leukocytes from human peripheral blood by the Hypaque-Ficoll method. *J Immunol Methods* 36:109–117
- Fialkow L, Wang Y, Downey GP (2007) Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. *Free Radic Biol Med* 42:153–164
- Fontana M, Mosca L, Rosei MA (2001) Interaction of enkephalins with oxyradicals. *Biochem Pharmacol* 61:1253–1257
- Fontana M, Pecci L, Schininà ME, Montefoschi G, Rosei MA (2006) Oxidative and nitrative modifications of enkephalins by reactive nitrogen species. *Free Radic Res* 40:697–706
- Frederickson RCA (1977) Enkephalin pentapeptides. A review of current evidence for a physiological role in vertebrate neurotransmission. *Life Sci* 21:23–42
- Goldstein S, Czapski G, Lind J, Merenyi G (1998) Mechanism of decomposition of peroxynitric ion (O₂NOO⁻): evidence for the formation of O₂⁻ and NO₂ radicals. *Inorg Chem* 37:3943–3947
- Grisham MB, Jourdain D, Wink DA (1999) Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. *Am J Physiol Gastrointest Liver Physiol* 276:G315–G321
- Hampton MB, Kettle AJ, Winterbourn CC (1998) Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. *Blood* 92:3007–3017
- Hampton MB, Vissers MC, Keenan JJ, Winterbourn CC (2002) Oxidant-mediated phosphatidylserine exposure and macrophages uptake of activated neutrophils: possible impairment in chronic granulomatous disease. *J Leukoc Biol* 71:775–781
- Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morris HR (1975) Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature* 258:577–579
- Hunter EPL, Desrosiers MF, Simic MG (1989) The effect of oxygen, antioxidants, and superoxide radical on tyrosyl phenoxyl radical dimerization. *Free Radic Biol Med* 6:581–585
- Jin F, Leicht J, von Sonntag G (1993) The superoxide radical reacts with tyrosine-derived phenoxyl radical by addition rather than electron transfer. *J Chem Soc Perkin Trans* 2:1583–1588
- Kasahara Y, Iway K, Yachi A, Ohta K, Konno A, Seki H, Miyawaki T, Taniguchi N (1997) Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. *Blood* 89:1748–1753
- Kettle AJ, Gedge CA, Hampton MB, Winterbourn CC (1995) Inhibition of myeloperoxidase by benzoic acid hydrazides. *Biochem J* 308:559–563
- Kettritz R, Falk RJ, Jennette JC, Gaido ML (1997) Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF α -mediated apoptosis. *J Am Soc Nephrol* 8:1091–1100
- Khwaja A, Tatton L (1999) Caspase-mediated proteolysis and activation of protein kinase C δ plays a central role in neutrophil apoptosis. *Blood* 94:291–301
- Lee A, Whyte MKB, Haslett C (1993) Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. *J Leukoc Biol* 54:283–288
- Lehmeyer JE, Snyderman R, Johnston RB (1979) Stimulation of neutrophil oxidative metabolism by chemotactic peptides: influence of calcium ion concentration and cytochalasin B and comparison with stimulation by phorbol myristate acetate. *Blood* 54:35–45
- Lim DG, Sweeney S, Bloodworth A, White CR, Chumley PH, Krishna NR, Schopfer F, O'Donnell VB, Eiserich JP, Freeman BA (2002) Nitrolinoleate, a nitric oxide-derived mediator of cell

- function: synthesis, characterization, and vasomotor activity. *Proc Natl Acad Sci USA* 99:15941–15946
- Lopker A, Abood LG, Hoss W, Lionetti FJ (1980) Stereoselective muscarinic acetylcholine and opiate receptors in human phagocytic leukocytes. *Biochem Pharmacol* 29:1361–1365
- McCain HV, Lamster IB, Bozzoni JM, Grbic JT (1982) B-endorphin modulates human immune activity via non-opiate receptor mechanisms. *Life Sci* 31:1619–1624
- Menzebach A, Hirsch J, Hempelmann G, Welters ID (2003) Effects of endogenous and synthetic opioid peptides on neutrophil function in vitro. *Br J Anaesth* 91:546–550
- Moilanen E, Vuorinen P, Kankaanranta H, Metsä-Ketelä T, Vapaatalo H (1993) Inhibition by nitric-oxide donors of human polymorphonuclear leukocyte functions. *Br J Pharmacol* 109:852–858
- Nagy P, Kettle AJ, Winterbourn CC (2009) Superoxide-mediated formation of tyrosine hydroperoxides and methionine sulfoxide in peptides through radical addition and intramolecular oxygen transfer. *J Biol Chem* 284:14723–14733
- Nagy P, Kettle AJ, Winterbourn CC (2010) Neutrophil-mediated oxidation of enkephalins via myeloperoxidase-dependent addition of superoxide. *Free Radic Biol Med* 49:792–799
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL, Miller DK (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. *Nature* 376:37–43
- Ottone L, Frumento G, Arduino N, Bertolotto M, Dapino P, Mancini M, Dallegri F (2002) Differential regulation of spontaneous and immune complex-induced neutrophil apoptosis by proinflammatory cytokines. Role of oxidants, Bax and caspase-3. *J Leukoc Biol* 72:125–132
- Padrós MR, Vindrola O, Zunszain P, Fainboin L, Finkielman S, Nahmod VE (1989) Mitogenic activation of the human lymphocytes induce the release of proenkephalin derived peptides. *Life Sci* 45:1805–1811
- Pasnik J, Tchorzewski H, Baj Z, Luciak M, Tchorzewski M (1999) Priming effect of met-enkephalin and beta-endorphin on chemiluminescence, chemotaxis and CD11b molecule expression on human neutrophils in vitro. *Immunol Lett* 67:77–83
- Pierzchala K, Van Loon GR (1990) Plasma native and peptidase-derivable Met-enkephalin responses to restraint stress in rats. Adaptation to repeated restraint. *J Clin Invest* 85:861–873
- Pongracz J, Webb P, Wang K, Deacon E, Lunn OJ, Lord JM (1999) Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein kinase C- δ . *J Biol Chem* 274:37329–37334
- Pruz WA, Monig H, Butler J, Land EJ (1985) Reactions of nitrogen dioxide in aqueous model systems: oxidation of tyrosine units in peptides and proteins. *Arch Biochem Biophys* 243:125–134
- Pryor WA, Squadrito GL (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 268:L699–L722
- Przewlocki R, Hassan AH, Lason W, Epplen C, Herz A, Stein C (1992) Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. *Neuroscience* 48:491–500
- Quijano C, Romero N, Radi R (2005) Tyrosine nitration by superoxide and nitric oxide fluxes in biological systems: modeling the impact of superoxide dismutase and nitric oxide diffusion. *Free Rad Biol Med* 39:728–741
- Rabgaoui N, Slaoui-Hasnaoui A, Torrelles J (1993) Boomerang effect between [Met]-enkephalin derivatives and human polymorphonuclear leukocytes. *Free Radic Biol Med* 14:519–529
- Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A (2001) Unraveling peroxynitrite formation in biological system. *Free Radic Biol Med* 30:463–488
- Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schäfer M, Stein C (2001) Opioid peptide expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. *Anesthesiology* 95:500–508
- Rosei MA (2001) Opiomelanins synthesis and properties. *Histol Histopathol* 16:931–935
- Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. *Nature* 407:770–776
- Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C (1989) Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. *J Clin Invest* 83:865–875
- Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. *Nat Rev Immunol* 2:965–975
- Scheel-Toellner D, Wang K, Craddock R, Webb PR, McGettrick HM, Assi LK, Parkes N, Clough LE, Gulbins E, Salmon M, Lord JM (2004) Reactive oxygen species limit neutrophil life span by activating death receptor signaling. *Blood* 104:2557–2564
- Semmoum Y, Younes A, Courdet J (2001) Effects of ischemia on the metabolism of cardiac enkephalins. *Arch Physiol Biochem* 109:18–23
- Sibinga NES, Goldstein A (1988) Opioid peptides and opioid receptors in cells of the immune system. *Ann Rev Immunol* 6:219–249
- Simon HU (2003) Neutrophil apoptosis pathways and their modifications in inflammation. *Immunol Rev* 193:101–110
- Sklar LA, McNeil VM, Jesaitis AJ, Painter RG, Cochrane CG (1982) A continuous, spectroscopic analysis of the kinetics of elastase secretion by neutrophils. The dependence of secretion upon receptor occupancy. *J Biol Chem* 257:5471–5475
- Souza JM, Peluffo G, Radi R (2008) Protein tyrosine nitration—functional alteration or just a biomarker? *Free Radic Biol Med* 45:357–366
- Stein C, Hassan AH, Przewlocki R, Gramsch C, Peter K, Herz A (1990) Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci USA* 87:5935–5939
- Sulowska Z, Majewska E, Krawczyk K, Klink M, Tchorzewski H (2002) Influence of opioid peptides on human neutrophil apoptosis and activation in vitro. *Mediators Inflamm* 11:245–250
- Terenius L, Whalstrom A, Lindeberg G, Karlsson S, Ragnarsson U (1976) Opiate receptor affinity of peptides related to Leu-enkephalin. *Biochem Biophys Res Commun* 71:175–179
- Torre D, Ferrario G, Speranza F, Orani A, Fiori GP, Zeroli C (1996) Serum concentrations of nitrite in patients with HIV-1 infection. *J Clin Pathol* 49:574–576
- Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropoulos H (2004) Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. *J Biol Chem* 279:8820–8826
- Vindrola O, Padrós MR, Sterin-Prync A, Ase A, Finkielman S, Nahmod VE (1990) Proenkephalin system in human polymorphonuclear cells. Production and release of a novel 1.0 kD peptide derived from synenkephalin. *J Clin Invest* 86:531–537
- Weinmann P, Gaehtgens P, Walzog B (1999) Bcl-X_L- and Bax- α -mediated regulation of apoptosis of human neutrophils via caspase-3. *Blood* 93:3106–3115
- Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L (2000) Neutrophils: molecules, functions and pathophysiological aspects. *Lab Invest* 80:617–653